vs
渤健（BIIB）与KBR, INC.（KBR）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是KBR, INC.的1.2倍（$2.3B vs $1.9B），KBR, INC.净利率更高（6.0% vs -2.1%，领先8.1%），KBR, INC.同比增速更快（-0.8% vs -7.1%），渤健自由现金流更多（$468.0M vs $190.0M）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
KBR是一家总部位于美国的科技与工程企业，业务覆盖航空航天、国防、工业、情报、能源等多个领域，为美国国家航空航天局（NASA）的各类项目、全球合作航天机构及商业合作伙伴提供技术与服务支持。
BIIB vs KBR — 直观对比
营收规模更大
BIIB
是对方的1.2倍
$1.9B
营收增速更快
KBR
高出6.3%
-7.1%
净利率更高
KBR
高出8.1%
-2.1%
自由现金流更多
BIIB
多$278.0M
$190.0M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $1.9B |
| 净利润 | $-48.9M | $115.0M |
| 毛利率 | 78.3% | 14.0% |
| 营业利润率 | -2.5% | 9.9% |
| 净利率 | -2.1% | 6.0% |
| 营收同比 | -7.1% | -0.8% |
| 净利润同比 | -118.3% | 15.0% |
| 每股收益（稀释后） | $-0.35 | $0.90 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBKBR
| Q4 25 | $2.3B | $1.9B | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $2.1B | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.3B | — |
净利润BIIBKBR
| Q4 25 | $-48.9M | $115.0M | ||
| Q3 25 | $466.5M | $73.0M | ||
| Q2 25 | $634.8M | $116.0M | ||
| Q1 25 | $240.5M | — | ||
| Q4 24 | $266.7M | — | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $583.6M | — | ||
| Q1 24 | $393.4M | — |
毛利率BIIBKBR
| Q4 25 | 78.3% | 14.0% | ||
| Q3 25 | 73.4% | 14.9% | ||
| Q2 25 | 77.1% | 14.5% | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBKBR
| Q4 25 | -2.5% | 9.9% | ||
| Q3 25 | 22.0% | 9.9% | ||
| Q2 25 | 28.1% | 9.5% | ||
| Q1 25 | 12.8% | — | ||
| Q4 24 | 11.9% | — | ||
| Q3 24 | 18.3% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.3% | — |
净利率BIIBKBR
| Q4 25 | -2.1% | 6.0% | ||
| Q3 25 | 18.4% | 3.7% | ||
| Q2 25 | 24.0% | 5.6% | ||
| Q1 25 | 9.9% | — | ||
| Q4 24 | 10.9% | — | ||
| Q3 24 | 15.8% | — | ||
| Q2 24 | 23.7% | — | ||
| Q1 24 | 17.2% | — |
每股收益（稀释后）BIIBKBR
| Q4 25 | $-0.35 | $0.90 | ||
| Q3 25 | $3.17 | $0.56 | ||
| Q2 25 | $4.33 | $0.88 | ||
| Q1 25 | $1.64 | — | ||
| Q4 24 | $1.82 | — | ||
| Q3 24 | $2.66 | — | ||
| Q2 24 | $4.00 | — | ||
| Q1 24 | $2.70 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $539.0M |
| 总债务越低越好 | $6.3B | $2.6B |
| 股东权益账面价值 | $18.3B | $1.5B |
| 总资产 | $29.4B | $6.6B |
| 负债/权益比越低杠杆越低 | 0.34× | 1.78× |
8季度趋势，按日历期对齐
现金及短期投资BIIBKBR
| Q4 25 | — | $539.0M | ||
| Q3 25 | — | $403.0M | ||
| Q2 25 | — | $442.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
总债务BIIBKBR
| Q4 25 | $6.3B | $2.6B | ||
| Q3 25 | $6.3B | $2.6B | ||
| Q2 25 | $6.3B | $2.7B | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — | ||
| Q1 24 | $6.3B | — |
股东权益BIIBKBR
| Q4 25 | $18.3B | $1.5B | ||
| Q3 25 | $18.2B | $1.5B | ||
| Q2 25 | $17.6B | $1.4B | ||
| Q1 25 | $17.0B | — | ||
| Q4 24 | $16.7B | — | ||
| Q3 24 | $16.4B | — | ||
| Q2 24 | $15.9B | — | ||
| Q1 24 | $15.2B | — |
总资产BIIBKBR
| Q4 25 | $29.4B | $6.6B | ||
| Q3 25 | $29.2B | $6.8B | ||
| Q2 25 | $28.3B | $6.8B | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $28.0B | — | ||
| Q3 24 | $28.3B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.6B | — |
负债/权益比BIIBKBR
| Q4 25 | 0.34× | 1.78× | ||
| Q3 25 | 0.35× | 1.76× | ||
| Q2 25 | 0.36× | 1.94× | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — | ||
| Q1 24 | 0.41× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $198.0M |
| 自由现金流经营现金流 - 资本支出 | $468.0M | $190.0M |
| 自由现金流率自由现金流/营收 | 20.5% | 9.8% |
| 资本支出强度资本支出/营收 | 1.9% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBKBR
| Q4 25 | $511.9M | $198.0M | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $160.9M | $98.0M | ||
| Q1 25 | $259.3M | — | ||
| Q4 24 | $760.9M | — | ||
| Q3 24 | $935.6M | — | ||
| Q2 24 | $625.8M | — | ||
| Q1 24 | $553.2M | — |
自由现金流BIIBKBR
| Q4 25 | $468.0M | $190.0M | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | $89.0M | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — | ||
| Q1 24 | $507.3M | — |
自由现金流率BIIBKBR
| Q4 25 | 20.5% | 9.8% | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | 4.3% | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.1% | — |
资本支出强度BIIBKBR
| Q4 25 | 1.9% | 0.4% | ||
| Q3 25 | 1.8% | 0.4% | ||
| Q2 25 | 1.0% | 0.4% | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.0% | — |
现金转化率BIIBKBR
| Q4 25 | — | 1.72× | ||
| Q3 25 | 2.73× | — | ||
| Q2 25 | 0.25× | 0.84× | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | — | ||
| Q2 24 | 1.07× | — | ||
| Q1 24 | 1.41× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
KBR
| U.S.Government Defense And Intelligence Clients | $832.0M | 43% |
| Sustainable Technology Solutions | $525.0M | 27% |
| Science And Space | $292.0M | 15% |
| Corporate Joint Venture | $172.0M | 9% |
| Commercial And Infrastructure | $64.0M | 3% |
| Other | $46.0M | 2% |
